Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types-Reference-Cited by-同舟云学术

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types

Published:2021-11 Issue:5 Volume: Page:1270-1280
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Takamatsu Shiro¹^ORCID,Brown J.B.²³^ORCID,Yamaguchi Ken¹^ORCID,Hamanishi Junzo¹^ORCID,Yamanoi Koji¹^ORCID,Takaya Hisamitsu⁴^ORCID,Kaneyasu Tomoko⁵,Mori Seiichi⁵,Mandai Masaki¹^ORCID,Matsumura Noriomi⁴^ORCID

Affiliation:

1. Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan

2. Life Science Informatics Research Unit, Department of Molecular Biosciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan

3. Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

4. Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan

5. Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan

Abstract

EXPRESSION OF CONCERN The Original Report by Takamatsu et al entitled, “Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types,” ( JCO Prec Onc 10.1200/PO.21.00141) published in JCO Precision Oncology on August 11, 2021, is under further review. Until the authors and their institutions can fully provide additional information, readers should interpret the findings presented with caution. An update will be provided when our investigation is complete.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.21.00141

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study;Future Oncology;2024-07-16

2. Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy;2024-01-10

3. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies;Cancer Research Communications;2023-11-06

4. Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis;Cancers;2023-09-19

5. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation;Genes;2023-08-25